{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:45:05Z","timestamp":1791881105229,"version":"4.3.4"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The primary objective of this systematic review was to evaluate the\ntherapeutic efficacy and safety profile of intralesional Ionic Contra-Viral Therapy (ICVT)-a\ncombination of digoxin and furosemide-in the treatment of multiple cutaneous warts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This meta-analysis was conducted in accordance with PRISMA guidelines and was\nprospectively registered in PROSPERO (CRD42024544551). A comprehensive literature\nsearch was performed up to April 2024 across PubMed, MEDLINE, Scopus, Cochrane CENTRAL,\nClinicalTrials.gov, and Google Scholar. Eligible studies included randomized controlled\ntrials involving adults with \u22652 cutaneous warts treated with intralesional digoxin and furosemide,\nassessing outcomes, such as complete and partial clearance, wart size reduction, and\nadverse events. Exclusion criteria included case reports, reviews, and preclinical studies. Data\nextraction was performed independently by two reviewers, with discrepancies resolved through\nconsensus. The Cochrane RoB 2 tool was used for risk of bias assessment. Meta-analyses were\nconducted using a random-effects model, and heterogeneity was evaluated using the I\u00b2 statistic.\nThe quality of evidence was graded using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seven randomized trials, including a total of 391 patients, were analyzed. The ICVT\ngroup demonstrated significantly higher complete wart clearance compared to placebo (56.8%\nvs. 2.8%; RR = 13.27, 95% CI = 2.93-60.17; p = 0.0018). Partial response was lower in the\nICVT group (5.08% vs. 10%; RR = 0.66, 95% CI = 0.09-5.09; p = 0.69). Adverse events occurred\nmore frequently in the ICVT group (85% vs. 58.8%; RR = 1.33, 95% CI = 0.47-3.79; p =\n0.59; I\u00b2 = 97%). Pain during injection was also more commonly reported in the ICVT group\n(96.6% vs. 63.3%; RR = 1.45, 95% CI = 0.29-7.22; p = 0.65; I\u00b2 = 99%). The certainty of evidence\nwas rated as very low for complete clearance, moderate for partial response, and low for\nadverse events and injection pain. Trial Sequential Analysis (TSA) indicated that the required\ninformation size was not met for any of the outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>While the results suggest that ICVT may be effective in achieving complete clearance\nof multiple cutaneous warts, the current evidence is limited by small sample sizes, methodological\nheterogeneity, and potential biases. The higher incidence of adverse events and injectionrelated\npain raises safety concerns. The low to very low certainty of evidence, coupled with the\nTSA findings, underscores the need for more rigorous investigation. Variability in trial design,\ndosing protocols, and outcome reporting further limits the applicability of current findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Intralesional ICVT shows promise as a therapeutic option for multiple cutaneous\nwarts, particularly in achieving complete clearance. However, due to the limited certainty of\navailable evidence and inconsistent safety data, further large-scale, high-quality randomized\ncontrolled trials are necessary to validate these findings and establish standardized treatment\nprotocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0125899775373642250630065739","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:54:33Z","timestamp":1753858473000},"page":"267-284","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-3262","authenticated-orcid":true,"given":"Madhusudan Prasad","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kanti Devi Medical College, Mathura, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1468-3083.2006.01833.x","volume":"21","author":"Kyriakis K.P.","year":"2007","unstructured":"Kyriakis K.P.; Pagana G.; Michailides C.; Emmanuelides S.; Palamaras I.; Terzoudi S.; Lifetime prevalence fluctuations of common and plane viral warts. J Eur Acad Dermatol Venereol  2007,21(2),260-262","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1046\/j.1365-2133.2001.04066.x","volume":"144","author":"Sterling J.C.","year":"2001","unstructured":"Sterling J.C.; Handfield-Jones S.; Hudson P.M.; Guidelines for the management of cutaneous warts. Br J Dermatol  2001,144(1),4-11","journal-title":"Br J Dermatol"},{"key":"ref=3","first-page":"1710","volume":"2009","author":"Loo S.K.","year":"2009","unstructured":"Loo S.K.; Tang W.Y.; Warts (non-genital). BMJ Clin Evid  2009,2009,1710","journal-title":"BMJ Clin Evid"},{"key":"ref=4","first-page":"1710","volume":"2007","author":"Nai-Ming L.","year":"2007","unstructured":"Nai-Ming L.; Yuk-Ming William T.; Warts (non-genital). BMJ Clin Evid  2007,2007,1710","journal-title":"BMJ Clin Evid"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7556\/jaoa.2018.024","volume":"118","author":"Witchey D.J.","year":"2018","unstructured":"Witchey D.J.; Witchey N.B.; Roth-Kauffman M.M.; Kauffman M.K.; Plantar warts: Epidemiology, pathophysiology, and clinical management. J Am Osteopath Assoc  2018,118(2),92-105","journal-title":"J Am Osteopath Assoc"},{"key":"ref=6","first-page":"1602","volume":"2010","author":"Buck H.","year":"2010","unstructured":"Buck H.; Jr W.; Warts (genital). BMJ Clin Evid  2010,2010,1602","journal-title":"BMJ Clin Evid"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/archderm.1963.01590150022004","volume":"87","author":"Massing A.M.","year":"1963","unstructured":"Massing A.M.; Epstein W.L.; Natural history of warts. A two-year study. Arch Dermatol  1963,87(3),306-310","journal-title":"Arch Dermatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1440-0960.1996.tb01010.x","volume":"37","author":"Kilkenny M.","year":"1996","unstructured":"Kilkenny M.; Marks R.; The descriptive epidemiology of warts in the community. Australas J Dermatol  1996,37(2),80-86","journal-title":"Australas J Dermatol"},{"key":"ref=9","first-page":"CD001781","volume":"2012","author":"Kwok C.S.","year":"2012","unstructured":"Kwok C.S.; Gibbs S.; Bennett C.; Holland R.; Abbott R.; Topical treatments for cutaneous warts. Cochrane Database Syst Rev  2012,2012(9),CD001781","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2133.2011.10218.x","volume":"165","author":"Kwok C.S.","year":"2011","unstructured":"Kwok C.S.; Holland R.; Gibbs S.; Efficacy of topical treatments for cutaneous warts: A meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol  2011,165(2),233-246","journal-title":"Br J Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"g339","DOI":"10.1136\/bmj.g3339","volume":"348","author":"Lynch MD","year":"2014","unstructured":"Lynch MD; Cliffe J; Morris-Jones R; Management of cutaneous viral warts. BMJ  2014,348(may27 8),g339","journal-title":"BMJ"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/j.1365-2133.2004.05847.x","volume":"150","author":"Harwood C.A.","year":"2004","unstructured":"Harwood C.A.; Surentheran T.; Sasieni P.; Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol  2004,150(5),949-957","journal-title":"Br J Dermatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e16989","DOI":"10.1016\/j.heliyon.2023.e16989","volume":"9","author":"Tao Z.","year":"2023","unstructured":"Tao Z.; Ran L.; Jian-Hua W.; Epidemiological survey of warts in Chinese military recruits: A cross-sectional and follow-up study. Heliyon  2023,9(6),e16989","journal-title":"Heliyon"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1155\/2007\/942650","volume":"23","author":"Nindl I.","year":"2007","unstructured":"Nindl I.; Gottschling M.; Stockfleth E.; Human papillomaviruses and non-melanoma skin cancer: Basic virology and clinical manifestations. Dis Markers  2007,23(4),247-259","journal-title":"Dis Markers"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4103\/idoj.idoj_492_22","volume":"14","author":"Jagati A.","year":"2023","unstructured":"Jagati A.; Chaudhary M.; Brar A.; Agarwal P.; Chavda V.; Rathod S.; A study of comparison and evaluation of various intralesional therapies in cutaneous warts. Indian Dermatol Online J  2023,14(4),487-492","journal-title":"Indian Dermatol Online J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/pde.14094","volume":"37","author":"Fields J.R.","year":"2020","unstructured":"Fields J.R.; Saikaly S.K.; Schoch J.J.; Intralesional immunotherapy for pediatric warts: A review. Pediatr Dermatol  2020,37(2),265-271","journal-title":"Pediatr Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1468-3083.2008.02719.x","volume":"22","author":"Gupta S.","year":"2008","unstructured":"Gupta S.; Malhotra A.K.; Verma K.K.; Sharma V.K.; Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano\u2010genital warts: An open label pilot study. J Eur Acad Dermatol Venereol  2008,22(9),1089-1093","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1370\/afm.1508","volume":"11","author":"Bruggink S.C.","year":"2013","unstructured":"Bruggink S.C.; Eekhof J.A.H.; Egberts P.F.; van Blijswijk S.C.E.; Assendelft W.J.J.; Gussekloo J.; Natural course of cutaneous warts among primary schoolchildren: A prospective cohort study. Ann Fam Med  2013,11(5),437-441","journal-title":"Ann Fam Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.clindermatol.2013.08.014","volume":"32","author":"Fathi R.","year":"2014","unstructured":"Fathi R.; Tsoukas M.M.; Genital warts and other HPV infections: Established and novel therapies. Clin Dermatol  2014,32(2),299-306","journal-title":"Clin Dermatol"},{"key":"ref=20","first-page":"10","volume":"44","author":"Rezai M.S.","year":"2019","unstructured":"Rezai M.S.; Ghasempouri H.; Asqary Marzidareh O.; Yazdani Cherati J.; Rahmatpour Rokni G.; Intralesional injection of the measles-mumps-rubella vaccine into resistant palmoplantar warts: A randomized controlled trial. Iran J Med Sci  2019,44(1),10-17","journal-title":"Iran J Med Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e13442","DOI":"10.1111\/srt.13442","volume":"29","author":"Al-Sabak H.","year":"2023","unstructured":"Al-Sabak H.; Al-Hattab M.; Al-Rammahi M.; Al-Dhalimi M.; The efficacy of intralesional vitamin D3 injection in the treatment of cutaneous warts: A clinical therapeutic trial study. Skin Res Technol  2023,29(8),e13442","journal-title":"Skin Res Technol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/2277-9175.129701","volume":"3","author":"Mobasher P.","year":"2014","unstructured":"Mobasher P.; Zamanian A.; Jazi G.; Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res  2014,3(1),107","journal-title":"Adv Biomed Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1067\/S0002-9378(03)00789-0","volume":"189","author":"Gunter J.","year":"2003","unstructured":"Gunter J.; Genital and perianal warts: New treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol  (Suppl.)2003,189(3),S3-S11","journal-title":"Am J Obstet Gynecol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/jebm.12494","volume":"15","author":"Zhu P.","year":"2022","unstructured":"Zhu P.; Qi R.Q.; Yang Y.; Clinical guideline for the diagnosis and treatment of cutaneous warts (2022). J Evid Based Med  2022,15(3),284-301","journal-title":"J Evid Based Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3121\/cmr.4.4.273","volume":"4","author":"Lipke M.M.","year":"2006","unstructured":"Lipke M.M.; An armamentarium of wart treatments. Clin Med Res  2006,4(4),273-293","journal-title":"Clin Med Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/vaccines12030228","volume":"12","author":"\u0218andru F.","year":"2024","unstructured":"\u0218andru F.; Radu A.M.; Petca A.; Dumitra\u0219cu M.C.; Petca R.C.; Roman A.M.; Unveiling the therapeutic horizon: HPV vaccines and their impact on cutaneous diseases\u2014A comprehensive review. Vaccines  2024,12(3),228","journal-title":"Vaccines"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5826\/dpc.1402a66","volume":"14","author":"Fouda I.","year":"2024","unstructured":"Fouda I.; Mohammed H.A.K.; Mohammed G.M.Y.; Intralesional quadrivalent human papilloma virus vaccine versus candida antigen in the treatment of multiple recalcitrant non-genital warts. Dermatol Pract Concept  2024,14(2),12","journal-title":"Dermatol Pract Concept"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/bmj.325.7362.461","volume":"325","author":"Gibbs S.","year":"2002","unstructured":"Gibbs S.; Harvey I.; Sterling J.; Stark R.; Local treatments for cutaneous warts: Systematic review * Commentary: Systematic reviewers face challenges from varied study designs. BMJ  2002,325(7362),461","journal-title":"BMJ"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1365-2230.2006.02105.x","volume":"31","author":"Luk N.M.","year":"2006","unstructured":"Luk N.M.; Tang W.Y.M.; Tang N.L.S.; Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: A single-centre, double-blind, randomized, placebo-controlled trial. Clin Exp Dermatol  2006,31(3),394-397","journal-title":"Clin Exp Dermatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5021\/ad.2011.23.3.282","volume":"23","author":"Choi J.W.","year":"2011","unstructured":"Choi J.W.; Cho S.; Lee J.H.; Does immunotherapy of viral warts provide beneficial effects when it is combined with conventional therapy? Ann Dermatol  2011,23(3),282-287","journal-title":"Ann Dermatol"},{"key":"ref=31","first-page":"690","volume":"87","author":"Khaled A.","year":"2009","unstructured":"Khaled A.; Ben Romdhane S.; Kharfi M.; Zeglaoui F.; Fazaa B.; Kamoun M.R.; Assessment of cryotherapy by liquid nitrogen in the treatment of hand and feet warts. Tunis Med  2009,87(10),690-692","journal-title":"Tunis Med"},{"key":"ref=32","first-page":"1174","volume":"10","author":"Nguyen N.V.","year":"2011","unstructured":"Nguyen N.V.; Burkhart C.G.; Cryosurgical treatment of warts: Dimethyl ether and propane versus liquid nitrogen - Case report and review of the literature. J Drugs Dermatol  2011,10(10),1174-1176","journal-title":"J Drugs Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1365-2133.2001.04449.x","volume":"145","author":"Connolly M.","year":"2001","unstructured":"Connolly M.; Bazmi K.; O\u2019Connell M.; Lyons J.F.; Bourke J.F.; Cryotherapy of viral warts: A sustained 10-s freeze is more effective than the traditional method. Br J Dermatol  2001,145(4),554-557","journal-title":"Br J Dermatol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"adv40819","DOI":"10.2340\/actadv.v104.40819","volume":"104","author":"Chang C.H.","year":"2024","unstructured":"Chang C.H.; Sung Z.Y.; Huang Y.C.; Efficacy of intralesional candida injection in the treatment of cutaneous warts: A systematic review and meta-analysis. Acta Derm Venereol  2024,104,adv40819","journal-title":"Acta Derm Venereol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1503\/cmaj.092194","volume":"182","author":"Bruggink S.C.","year":"2010","unstructured":"Bruggink S.C.; Gussekloo J.; Berger M.Y.; Zaaijer K.; Assendelft W.J.; de Waal M.W.; Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: Randomized controlled trial. CMAJ  2010,182(15),1624-1630","journal-title":"CMAJ"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00403-023-02698-z","volume":"315","author":"Fawzy M.","year":"2023","unstructured":"Fawzy M.; Nofal E.; Abdelkhalek N.; Ehab R.; Intralesional bivalent and quadrivalent human papillomavirus vaccines didn\u2019t significantly enhance the response of multiple anogenital warts when co-administered with intralesional Candida antigen immunotherapy. A randomized controlled trial. Arch Dermatol Res  2023,315(10),2813-2823","journal-title":"Arch Dermatol Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40257-020-00582-4","volume":"22","author":"Friedman P.C.","year":"2021","unstructured":"Friedman P.C.; Management of difficult-to-treat warts: Traditional and new approaches. Am J Clin Dermatol  2021,22(3),379-394","journal-title":"Am J Clin Dermatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/dth.12352","volume":"29","author":"Aldahan A.S.","year":"2016","unstructured":"Aldahan A.S.; Mlacker S.; Shah V.V.; Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature. Dermatol Ther  2016,29(3),197-207","journal-title":"Dermatol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.4103\/0019-5154.117301","volume":"58","author":"Majid I.","year":"2013","unstructured":"Majid I.; Imran S.; Immunotherapy with intralesional Candida albicansantigen in resistant or recurrent warts: A study. Indian J Dermatol  2013,58(5),360-365","journal-title":"Indian J Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/CS20050369","volume":"110","author":"Doorbar J.","year":"2006","unstructured":"Doorbar J.; Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci  2006,110(5),525-541","journal-title":"Clin Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1525-1470.2003.20318.x","volume":"20","author":"Clifton M.M.","year":"2003","unstructured":"Clifton M.M.; Johnson S.M.; Roberson P.K.; Kincannon J.; Horn T.D.; Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol  2003,20(3),268-271","journal-title":"Pediatr Dermatol"},{"key":"ref=42","first-page":"263","volume":"3","author":"Johnson S.M.","year":"2004","unstructured":"Johnson S.M.; Horn T.D.; Intralesional immunotherapy for warts using a combination of skin test antigens: A safe and effective therapy. J Drugs Dermatol  2004,3(3),263-265","journal-title":"J Drugs Dermatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/archderm.141.12.1606","volume":"141","author":"King M.","year":"2005","unstructured":"King M.; Johnson S.M.; Horn T.D.; Intralesional immunotherapy for genital warts. Arch Dermatol  2005,141(12),1606-1607","journal-title":"Arch Dermatol"},{"key":"ref=44","first-page":"288","volume":"84","author":"Mulhem E.","year":"2011","unstructured":"Mulhem E.; Pinelis S.; Treatment of nongenital cutaneous warts. Am Fam Physician  2011,84(3),288-293","journal-title":"Am Fam Physician"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1046\/j.1365-2133.1996.d01-1104.x","volume":"135","author":"Munn S.E.","year":"1996","unstructured":"Munn S.E.; Higgins E.; Marshall M.; Clement M.; A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol  1996,135(6),969-971","journal-title":"Br J Dermatol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archderm.141.5.589","volume":"141","author":"Horn T.D.","year":"2005","unstructured":"Horn T.D.; Johnson S.M.; Helm R.M.; Roberson P.K.; Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: A single-blinded, randomized, and controlled trial. Arch Dermatol  2005,141(5),589-594","journal-title":"Arch Dermatol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","volume":"41","author":"Chesson H.W.","year":"2014","unstructured":"Chesson H.W.; Dunne E.F.; Hariri S.; Markowitz L.E.; The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis  2014,41(11),660-664","journal-title":"Sex Transm Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","volume":"324","author":"de Villiers E.M.","year":"2004","unstructured":"de Villiers E.M.; Fauquet C.; Broker T.R.; Bernard H.U.; zur Hausen H.; Classification of papillomaviruses. Virology  2004,324(1),17-27","journal-title":"Virology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/medicina58070860","volume":"58","author":"Gardella B.","year":"2022","unstructured":"Gardella B.; Gritti A.; Soleymaninejadian E.; New perspectives in therapeutic vaccines for HPV: A critical review. Medicina  2022,58(7),860","journal-title":"Medicina"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1394260","DOI":"10.3389\/fonc.2024.1394260","volume":"14","author":"Xu D.M.","year":"2024","unstructured":"Xu D.M.; Chen L.X.; Zhuang X.Y.; Han H.; Mo M.; Advances in molecular basis of response to immunotherapy for penile cancer: Better screening of responders. Front Oncol  2024,14,1394260","journal-title":"Front Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00281-023-00986-4","volume":"45","author":"Melief C.J.M.","year":"2023","unstructured":"Melief C.J.M.; van der Gracht E.; Wiekmeijer A.S.; Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16. Semin Immunopathol  2023,45(2),273-277","journal-title":"Semin Immunopathol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"857410","DOI":"10.3389\/fmicb.2022.857410","volume":"13","author":"Wu L.","year":"2022","unstructured":"Wu L.; Wang W.; Zhang J.; Detection of five types of HPV genotypes causing anogenital warts (Condyloma Acuminatum) using PCR-Tm analysis technology. Front Microbiol  2022,13,857410","journal-title":"Front Microbiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jiac.2023.01.017","volume":"29","author":"Sarier M.","year":"2023","unstructured":"Sarier M.; Sepin N.; Emek M.; Konuk E.Y.; Kaplan T.; Yuksel B.A.; Evaluation of the optimal sampling approach for HPV genotyping in circumcised heterosexual men with genital warts. J Infect Chemother  2023,29(5),475-480","journal-title":"J Infect Chemother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/21645515.2015.1103936","volume":"12","author":"Turner T.B.","year":"2016","unstructured":"Turner T.B.; Huh W.K.; HPV vaccines: Translating immunogenicity into efficacy. Hum Vaccin Immunother  2016,12(6),1403-1405","journal-title":"Hum Vaccin Immunother"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/jcm11041101","volume":"11","author":"Rafael T.S.","year":"2022","unstructured":"Rafael T.S.; Rotman J.; Brouwer O.R.; Immunotherapeutic approaches for the treatment of HPV-associated (Pre-)Cancer of the Cervix, Vulva and Penis. J Clin Med  2022,11(4),1101","journal-title":"J Clin Med"},{"key":"ref=56","first-page":"455","volume":"10","author":"Link F.","year":"1966","unstructured":"Link F.; Sz\u00e1nt\u00f3 J.; Blaskovic D.; Raus J.; Dobrock\u00e1 E.; Pristasov\u00e1 S.; Interaction of heart glycosides and viruses. Acta Virol  1966,10(5),455-461","journal-title":"Acta Virol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/ijms19082154","volume":"19","author":"Amarelle L.","year":"2018","unstructured":"Amarelle L.; Lecuona E.; The antiviral effects of Na,K-ATPase inhibition: A minireview. Int J Mol Sci  2018,19(8),2154","journal-title":"Int J Mol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00705-006-0824-x","volume":"151","author":"Hartley C.","year":"2006","unstructured":"Hartley C.; Hartley M.; Pardoe I.; Knight A.; Ionic Contra-Viral Therapy (ICVT); A new approach to the treatment of DNA virus infections. Arch Virol  2006,151(12),2495-2501","journal-title":"Arch Virol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","volume":"2003","author":"Bosch F.X.","year":"2003","unstructured":"Bosch F.X.; de Sanjos\u00e9 S.; Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr  2003,2003(31),3-13","journal-title":"J Natl Cancer Inst Monogr"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"Sterne J.A.C.","year":"2019","unstructured":"Sterne J.A.C.; Savovi\u0107 J.; Page M.J.; RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ  2019,366,l4898","journal-title":"BMJ"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"Guyatt G.","year":"2011","unstructured":"Guyatt G.; Oxman A.D.; Akl E.A.; GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol  2011,64(4),383-394","journal-title":"J Clin Epidemiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","volume":"64","author":"Bro\u017cek J.L.","year":"2009","unstructured":"Bro\u017cek J.L.; Akl E.A.; Alonso-Coello P.; Grading quality of evidence and strength of recommendations in clinical practice guidelines. Allergy  2009,64(5),669-677","journal-title":"Allergy"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"Balshem H.","year":"2011","unstructured":"Balshem H.; Helfand M.; Sch\u00fcnemann H.J.; GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol  2011,64(4),401-406","journal-title":"J Clin Epidemiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"Brok J.","year":"2009","unstructured":"Brok J.; Thorlund K.; Wetterslev J.; Gluud C.; Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol  2009,38(1),287-298","journal-title":"Int J Epidemiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"Brok J.","year":"2008","unstructured":"Brok J.; Thorlund K.; Gluud C.; Wetterslev J.; Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol  2008,61(8),763-769","journal-title":"J Clin Epidemiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/biom11050659","volume":"11","author":"\u0160kubn\u00edk J.","year":"2021","unstructured":"\u0160kubn\u00edk J.; Pavl\u00ed\u010dkov\u00e1 V.; Rimpelov\u00e1 S.; Cardiac glycosides as immune system modulators. Biomolecules  2021,11(5),659","journal-title":"Biomolecules"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"143ra99","DOI":"10.1126\/scitranslmed.3003807","volume":"4","author":"Menger L.","year":"2012","unstructured":"Menger L.; Vacchelli E.; Adjemian S.; Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med  2012,4(143),143ra99","journal-title":"Sci Transl Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1111\/jdv.14527","volume":"31","author":"van der Kolk T.","year":"2017","unstructured":"van der Kolk T.; Dillingh M.R.; Rijneveld R.; Topical ionic contra\u2010viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts. J Eur Acad Dermatol Venereol  2017,31(12),2088-2090","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/jdv.15894","volume":"34","author":"Rijsbergen M.","year":"2020","unstructured":"Rijsbergen M.; Rijneveld R.; Todd M.; No effect of topical digoxin and furosemide gel for patients with external anogenital warts. J Eur Acad Dermatol Venereol  2020,34(1),e45-e46","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/bjd.17583","volume":"180","author":"Rijsbergen M.","year":"2019","unstructured":"Rijsbergen M.; Niemeyer-van der Kolk T.; Hogendoorn G.; A randomized controlled proof\u2010of\u2010concept trial of digoxin and furosemide in adults with cutaneous warts. Br J Dermatol  2019,180(5),1058-1068","journal-title":"Br J Dermatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.23736\/S0392-0488.18.06125-4","volume":"155","author":"Delmonte S.","year":"2020","unstructured":"Delmonte S.; Benardon S.; Cariti C.; Ribero S.; Ramoni S.; Cusini M.; Anogenital warts treatment options: A practical approach. G Ital Dermatol Venereol  2020,155(3),261-268","journal-title":"G Ital Dermatol Venereol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1099\/vir.0.039677-0","volume":"93","author":"Stanley M.A.","year":"2012","unstructured":"Stanley M.A.; Genital human papillomavirus infections: Current and prospective therapies. J Gen Virol  2012,93(4),681-691","journal-title":"J Gen Virol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1086\/342109","volume":"35","author":"Wiley DJ","year":"2002","unstructured":"Wiley DJ; Douglas J; Beutner K; External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis  (Suppl. 2)2002,35(s2),S210-24","journal-title":"Clin Infect Dis"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.66344\/jpad.v32i1.1795","volume":"32","author":"Siddiqui S.","year":"2022","unstructured":"Siddiqui S.; Comparison of efficacy of cryotherapy versus ionic contraviral therapy (ICVT) in the treatment of viral warts. J Pak Assoc Dermatol  2022,32(1),15-21","journal-title":"J Pak Assoc Dermatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"546","DOI":"10.36849\/JDD.5264","volume":"20","author":"Abdelaal M.A.","year":"2021","unstructured":"Abdelaal M.A.; Abdelaziz H.M.; Ahmed K.A.; Elsaie M.L.; Comparative study of intralesional vitamin d3 injection and candida albicans antigen in treating plantar warts. J Drugs Dermatol  2021,20(5),546-549","journal-title":"J Drugs Dermatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/pde.14280","volume":"37","author":"Mohta A.","year":"2020","unstructured":"Mohta A.; Kushwaha R.K.; Gautam U.; Sharma P.; Nyati A.; Jain S.K.; A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children. Pediatr Dermatol  2020,37(5),853-859","journal-title":"Pediatr Dermatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e34338","DOI":"10.7759\/cureus.34338","volume":"15","author":"Surani A.S.","year":"2023","unstructured":"Surani A.S.; Un R.; Marfatia Y.; Efficacy of intralesional measles mumps rubella vaccine in the treatment of verruca vulgaris: An interventional study. Cureus  2023,15(1),e34338","journal-title":"Cureus"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.xjidi.2024.100264","volume":"4","author":"Mullen S.A.","year":"2024","unstructured":"Mullen S.A.; Myers E.L.; Brenner R.L.; Nguyen K.T.; Harper T.A.; Welsh D.; Systematic review of intralesional therapies for cutaneous warts. JID Innov  2024,4(3),100264","journal-title":"JID Innov"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/jocd.15581","volume":"22","author":"Nasr M.","year":"2023","unstructured":"Nasr M.; Abdelaty S.; Elkholy B.M.; A comparative clinico\u2010dermoscopic study of intralesional injection of combined digoxin and furosemide, Candida antigen, and vitamin D3 for multiple warts. J Cosmet Dermatol  2023,22(4),1344-1353","journal-title":"J Cosmet Dermatol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2174\/18715206113139990304","volume":"13","author":"Babula P.","year":"2013","unstructured":"Babula P.; Masarik M.; Adam V.; Provaznik I.; Kizek R.; From Na+\/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment. Anticancer Agents Med Chem  2013,13(7),1069-1087","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/nrd2682","volume":"7","author":"Prassas I.","year":"2008","unstructured":"Prassas I.; Diamandis E.P.; Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov  2008,7(11),926-935","journal-title":"Nat Rev Drug Discov"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fncel.2015.00086","volume":"9","author":"Litan A.","year":"2015","unstructured":"Litan A.; Langhans S.A.; Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front Cell Neurosci  2015,9,86","journal-title":"Front Cell Neurosci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.3390\/molecules25163596","volume":"25","author":"Reddy D.","year":"2020","unstructured":"Reddy D.; Kumavath R.; Barh D.; Azevedo V.; Ghosh P.; Anticancer and antiviral properties of cardiac glycosides: A review to explore the mechanism of actions. Molecules  2020,25(16),3596","journal-title":"Molecules"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/molecules22111932","volume":"22","author":"Schneider N.","year":"2017","unstructured":"Schneider N.; Cerella C.; Sim\u00f5es C.M.O.; Diederich M.; Anticancer and immunogenic properties of cardiac glycosides. Molecules  2017,22(11),1932","journal-title":"Molecules"},{"key":"ref=85","first-page":"109","volume":"63","author":"Winnicka K.","year":"2006","unstructured":"Winnicka K.; Bielawski K.; Bielawska A.; Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm  2006,63(2),109-115","journal-title":"Acta Pol Pharm"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.4161\/onci.21684","volume":"1","author":"Kepp O.","year":"2012","unstructured":"Kepp O.; Menger L.; Vacchelli E.; Anticancer activity of cardiac glycosides. OncoImmunology  2012,1(9),1640-1642","journal-title":"OncoImmunology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/ddg.12838","volume":"149","author":"Ockenfels H.M.","year":"2016","unstructured":"Ockenfels H.M.; Therapeutic management of cutaneous and genital warts. J Dtsch Dermatol Ges  2016,149,892-899","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e15935","DOI":"10.1111\/dth.15935","volume":"35","author":"Lofty A.R.","year":"2022","unstructured":"Lofty A.R.; Elbakry A.M.; Omar G.A.B.; Hamdino M.; Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial. Dermatol Ther  2022,35(12),e15935","journal-title":"Dermatol Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00403-024-03014-z","volume":"316","year":"2024","unstructured":"khattab F, Essam R, Elhadidy RF, Anis N. Intralesional combined digoxin and furosemide versus intralesional 5-flurouracil for the treatment of recalcitrant plantar warts: A prospective, randomized study. Arch Dermatol Res  2024,316(7),411","journal-title":"Arch Dermatol Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1111\/jocd.13913","volume":"20","author":"Fathy G.","year":"2021","unstructured":"Fathy G.; Abo-Elmagd W.M.; Afify A.A.; Intralesional combined digoxin and furosemide in plantar warts: Does it work? J Cosmet Dermatol  2021,20(8),2606-2611","journal-title":"J Cosmet Dermatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/JCAS.JCAS_62_19","volume":"13","author":"Ringin S.","year":"2020","unstructured":"Ringin S.; The effectiveness of cutaneous wart resolution with current treatment modalities. J Cutan Aesthet Surg  2020,13(1),24-30","journal-title":"J Cutan Aesthet Surg"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5070\/D3263048027","volume":"26","author":"Muse M.E.","year":"2020","unstructured":"Muse M.E.; Stiff K.M.; Glines K.R.; Cline A.; Feldman S.R.; A review of intralesional wart therapy. Dermatol Online J  2020,26(3),263","journal-title":"Dermatol Online J"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"15450","DOI":"10.1038\/s41598-018-33511-x","volume":"8","author":"Liu J.","year":"2018","unstructured":"Liu J.; Li H.; Yang F.; Epidemiology and clinical profile of cutaneous warts in Chinese college students: A cross-sectional and follow-up study. Sci Rep  2018,8(1),15450","journal-title":"Sci Rep"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.conctc.2020.100534","volume":"17","author":"Redzic N.","year":"2020","unstructured":"Redzic N.; Benoy I.; Vanden Broeck D.; Bogers J.P.; Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial. Contemp Clin Trials Commun  2020,17,100534","journal-title":"Contemp Clin Trials Commun"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1396-0296.2004.04047.x","volume":"17","author":"Rivera A.","year":"2004","unstructured":"Rivera A.; Tyring S.K.; Therapy of cutaneous human Papillomavirus infections. Dermatol Ther  2004,17(6),441-448","journal-title":"Dermatol Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/092986709787002835","volume":"16","author":"Arcangeli A.","year":"2009","unstructured":"Arcangeli A.; Crociani O.; Lastraioli E.; Masi A.; Pillozzi S.; Becchetti A.; Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem  2009,16(1),66-93","journal-title":"Curr Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ijd.12480","volume":"54","author":"Nofal A.","year":"2015","unstructured":"Nofal A.; Nofal E.; Yosef A.; Nofal H.; Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: A promising approach. Int J Dermatol  2015,54(6),667-671","journal-title":"Int J Dermatol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/09546634.2020.1720585","volume":"32","author":"Attwa E.","year":"2021","unstructured":"Attwa E.; Elawady R.; Salah E.; \u2018Cryo-immuno-therapy\u2019 is superior to intralesional Candida antigen monotherapy in the treatment of multiple common warts. J Dermatolog Treat  2021,32(8),1018-1025","journal-title":"J Dermatolog Treat"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"d3271","DOI":"10.1136\/bmj.d3271","volume":"342","author":"Cockayne S","year":"2011","unstructured":"Cockayne S; Hewitt C; Hicks K; Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): A randomised controlled trial. BMJ  2011,342(jun07 1),d3271","journal-title":"BMJ"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/jid.2013.226","volume":"133","author":"Silverberg J.I.","year":"2013","unstructured":"Silverberg J.I.; Silverberg N.B.; The U.S. prevalence of common warts in childhood: A population-based study. J Invest Dermatol  2013,133(12),2788-2790","journal-title":"J Invest Dermatol"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775373642250630065739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/243899\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775373642250630065739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:52:27Z","timestamp":1791877947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/243899\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0125899775373642250630065739","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}